London-based Thriva raises €4.4 million Series A extension for its home blood tests

British startup Thriva, the ‘proactive health’ startup, has secured a €4.4 million extension to its Series A funding round from Target Global’s new Early Stage Fund II, which will top up the €6.7 million Series A raised in 2019. 

Thriva, founded in 2015, is rapidly becoming the go-to brand in the ‘proactive health’ category, an increasingly mainstream movement in which people are taking control of their own health. Thanks to Thriva, customers can understand, keep track of and improve what’s happening inside their bodies. Its at-home testing kits are processed by UKAS accredited laboratories and can analyse anything from indicators of heart disease and diabetes, to vitamins and minerals and hormone function. 

The startup has recently launched new personalised health plans and high quality supplements, which it delivers via partnerships with hospitals and other healthcare providers that wish to provide at-home testing to their patients and clients. So far the startup has processed over 115,000 test at-home blood tests in the last 4 years, with 76% of Thriva users achieving an improvement in at least one of their biomarkers between tests.

The company, which was founded by Hamish Grierson, Eliot Brooks and Tom Livesey, continues to grow 100% year-on-year and has expanded its team significantly to 50 team members in the company’s London Headquarters.

The investment, which takes Thriva’s total funding to around €12 million, will support the startup as it expands its at-home health service designed to help people stay on the front foot with their health and to continue putting better health in their hands.

Hamish Grierson, co-founder and CEO of Thriva said: “As the world faces unprecedented challenges posed by the coronavirus crisis, we have all been forced to view our health, and our mortality, in a new light. We believe that now and in the near future, people will be taking a more proactive approach to their own health and wellbeing. Whilst we cannot protect ourselves entirely from the tragic effects of a global pandemic like COVID-19, this period may inspire people to invest in their general health for the long-term.”

Dr Ricardo Schäfer, Partner at Target Global said: “When we first met the team behind Thriva, we were immediately hooked by their mission to allow people to take health into their own hands. Thriva has all the right ingredients to become one of those transforming category leaders we are seeking to back at Target Global. We are witnessing a shift in consumer behavior towards an increasingly proactive approach to health: people want to know what’s going on inside their bodies. Covid-19 is further accelerating this trend, which requires remote blood testing. Thriva is playing an essential role in providing a solution for increasing the test volume. We are excited to partner with Hamish, Eliot, and Tom at this pivotal point in time for the company.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here